rabbit anti rat vegfr 2  (Boster Bio)

Journal: International Journal of Biological Sciences

Article Title: Inhibition of Lymphangiogenesis of Endothelial Progenitor Cells with VEGFR-3 siRNA Delivered with PEI-alginate Nanoparticles

doi: 10.7150/ijbs.6719

Figure Lengend Snippet: Characteristics of CD34 + VEGFR-3 + EPCs. (A) There are CD34 + VEGFR-3 + cells and CD133 + VEGFR-3 + cells in the mononuclear cells isolated from umbilical cord blood. The cells were analyzed with a flow cytometer. (B) In immunostaining, VEGFR-3 + cells express CD34 and CD133. (C) Features of CD34 + VEGFR-3 + EPCs. After treatment with 50 ng/ml VEGF-C, the cells proliferate, the shape of the cells changes. (D) Expression of LYVE-1 on the differentiated cells. At day 14 after induction with VEGF-C, the cells are positive for LYVE-1 immunostaining. Bars = 25 μm.

Article Snippet: The mononuclear cells were incubated with mouse anti-human CD34 antibody (1:100; Diagnostica, NJ, USA) and rabbit anti-human VEGFR-3 antibody (1:100; Santa Cruz Biotechnology, CA, USA), or mouse anti-human CD133 antibody (1:100; Diagnostica, NJ, USA) and rabbit anti-human VEGFR-3 antibody (1:100) at 4°C for 50 min. Nonspecific antigen of the cells was blocked with 5% bovine serum albumin (BSA; GE Healthcare, London, UK).

Techniques: Isolation, Flow Cytometry, Immunostaining, Expressing

Journal: International Journal of Biological Sciences

Article Title: Inhibition of Lymphangiogenesis of Endothelial Progenitor Cells with VEGFR-3 siRNA Delivered with PEI-alginate Nanoparticles

doi: 10.7150/ijbs.6719

Figure Lengend Snippet: Characteristics of PEI-alginate nanoparticles in loading VEGFR-3 siRNA. (A) siRNA loading in the nanoparticles. The negative control siRNA was loaded with the nanoparticles with different N/P ratios. It is desirable for siRNA loading that N/P ratio is 16. (B) Viability of the cells after treatment with the nanoparticles loading negative control siRNA with different N/P ratios. Cell viability was determined with MTT assay after treatment for 24 h. * p < 0.05, ** p < 0.01 versus N/P ratio = 1 group (PEI/siRNA group); # p < 0.05, ## p < 0.01 versus N/P ratio = 1 group (PEI-alginate/siRNA group); † p < 0.05 versus PEI/siRNA group. n = 3.

Article Snippet: The mononuclear cells were incubated with mouse anti-human CD34 antibody (1:100; Diagnostica, NJ, USA) and rabbit anti-human VEGFR-3 antibody (1:100; Santa Cruz Biotechnology, CA, USA), or mouse anti-human CD133 antibody (1:100; Diagnostica, NJ, USA) and rabbit anti-human VEGFR-3 antibody (1:100) at 4°C for 50 min. Nonspecific antigen of the cells was blocked with 5% bovine serum albumin (BSA; GE Healthcare, London, UK).

Techniques: Negative Control, MTT Assay

Journal: International Journal of Biological Sciences

Article Title: Inhibition of Lymphangiogenesis of Endothelial Progenitor Cells with VEGFR-3 siRNA Delivered with PEI-alginate Nanoparticles

doi: 10.7150/ijbs.6719

Figure Lengend Snippet: Inhibition of VEGFR-3 mRNA expression after treatment with PEI-alginate/siRNA nanocomplexes. (A) Expression of VEGFR-3 mRNA. The cells were transfected with VEGFR-3 siRNA for 4 h. Inhibition of VEGFR-3 mRNA expression was analyzed with RT-PCR. Compared with VEGFR-3 siRNA #2 and VEGFR-3 siRNA #3, VEGFR-3 siRNA #1 inhibits expression of VEGFR-3 mRNA in the cells significantly. (B) Statistic results of VEGFR-3 mRNA expression. * p < 0.05, ** p < 0.01 versus the control group. n = 5.

Article Snippet: The mononuclear cells were incubated with mouse anti-human CD34 antibody (1:100; Diagnostica, NJ, USA) and rabbit anti-human VEGFR-3 antibody (1:100; Santa Cruz Biotechnology, CA, USA), or mouse anti-human CD133 antibody (1:100; Diagnostica, NJ, USA) and rabbit anti-human VEGFR-3 antibody (1:100) at 4°C for 50 min. Nonspecific antigen of the cells was blocked with 5% bovine serum albumin (BSA; GE Healthcare, London, UK).

Techniques: Inhibition, Expressing, Transfection, Reverse Transcription Polymerase Chain Reaction

Journal: International Journal of Biological Sciences

Article Title: Inhibition of Lymphangiogenesis of Endothelial Progenitor Cells with VEGFR-3 siRNA Delivered with PEI-alginate Nanoparticles

doi: 10.7150/ijbs.6719

Figure Lengend Snippet: Viability of the cells after transfection with VEGFR-3 siRNA in PEI-alginate nanoparticles. Cell viability was analyzed with MTT assay. After treatment with PEI-alginate/siRNA nanocomplexes (N/P = 16), viability of the cells decreases significantly. * p < 0.01 versus control and PEI-alginate groups; # p < 0.05 versus PEI-alginate group. n = 3.

Article Snippet: The mononuclear cells were incubated with mouse anti-human CD34 antibody (1:100; Diagnostica, NJ, USA) and rabbit anti-human VEGFR-3 antibody (1:100; Santa Cruz Biotechnology, CA, USA), or mouse anti-human CD133 antibody (1:100; Diagnostica, NJ, USA) and rabbit anti-human VEGFR-3 antibody (1:100) at 4°C for 50 min. Nonspecific antigen of the cells was blocked with 5% bovine serum albumin (BSA; GE Healthcare, London, UK).

Techniques: Transfection, MTT Assay

Journal: International Journal of Biological Sciences

Article Title: Inhibition of Lymphangiogenesis of Endothelial Progenitor Cells with VEGFR-3 siRNA Delivered with PEI-alginate Nanoparticles

doi: 10.7150/ijbs.6719

Figure Lengend Snippet: PCNA expression of the cells transfected with VEGFR-3 siRNA. (A) Microphotographs of PCNA expression in the cells. The cells were treated with PEI-alginate/siRNA nanocomplexes for 4 h. After removing excess nanocomplexes with medium exchange, the cells continued to be incubated for 20 h. Under VEGF-C induction, PCNA expression in the cells treated with the nanocomplexes decreases. Bar = 20 μm. (B) Statistic results of PCNA expression. The fluorescence density of the cells treated with the nanocomplexes decreases obviously. ** p < 0.01 versus control group; # p < 0.01 versus VEGF-C group; † p < 0.01 versus nanoparticle group. n = 3.

Article Snippet: The mononuclear cells were incubated with mouse anti-human CD34 antibody (1:100; Diagnostica, NJ, USA) and rabbit anti-human VEGFR-3 antibody (1:100; Santa Cruz Biotechnology, CA, USA), or mouse anti-human CD133 antibody (1:100; Diagnostica, NJ, USA) and rabbit anti-human VEGFR-3 antibody (1:100) at 4°C for 50 min. Nonspecific antigen of the cells was blocked with 5% bovine serum albumin (BSA; GE Healthcare, London, UK).

Techniques: Expressing, Transfection, Incubation, Fluorescence